Interleukin 23 receptor gene polymorphisms and their role in the inflammatory status of rheumatoid arthritis patients in an Iranian population.


Journal

International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930

Informations de publication

Date de publication:
Feb 2023
Historique:
revised: 10 09 2022
received: 14 06 2022
accepted: 11 10 2022
pubmed: 28 10 2022
medline: 31 1 2023
entrez: 27 10 2022
Statut: ppublish

Résumé

Several investigations have disclosed the involvement of the interleukin (IL)-23/IL-17 pathway in rheumatoid arthritis (RA) pathogenesis. Here we investigated the association of single nucleotide polymorphisms (SNPs) in the IL23 receptor (IL23R) gene with RA risk. In addition, the role of these SNPs with the inflammatory state of the patients were determined. In this case-control study, 200 RA cases and 200 healthy subjects were recruited. Using allelic discrimination real-time polymerase chain reaction, both IL23R rs10489629 and rs1004819 SNPs were genotyped. The messenger RNA (mRNA) expression levels of IL-23R, IL-23, and IL-17A were determined in peripheral blood mononuclear cells (PBMCs). The serum levels of IL-23 and IL-17A were also determined. The A allele (odds ratio [OR] = 1.52, 95% CI: 1.15-2.01; P = .0030), AA genotype (OR = 2.41, 95% CI: 1.33-4.35; P = .0035), and AG genotype (OR = 2.55, 95% CI: 1.56-4.16, P = .0002) of rs1004819 SNP was significantly associated with increased RA risk. The mRNA expression of IL-17A (fold change = 2.55, P = .00027), IL-23 (fold change = 1.62, P = .0081), and IL-23R (fold change = 1.59, P = .0077) was significantly upregulated in the PBMCs from RA patients compared to that of healthy controls. Serum levels of IL-17A (P = .00019) and IL-23 (P = .00055) was significantly higher in the RA patients compared to the controls. No significant association was detected between patient data and SNPs. The IL-23/IL-27 pathway plays a role in RA pathogenesis, but IL23R gene rs1004819 SNP might not be regulating this pathway in RA disease.

Sections du résumé

BACKGROUND BACKGROUND
Several investigations have disclosed the involvement of the interleukin (IL)-23/IL-17 pathway in rheumatoid arthritis (RA) pathogenesis. Here we investigated the association of single nucleotide polymorphisms (SNPs) in the IL23 receptor (IL23R) gene with RA risk. In addition, the role of these SNPs with the inflammatory state of the patients were determined.
METHODS METHODS
In this case-control study, 200 RA cases and 200 healthy subjects were recruited. Using allelic discrimination real-time polymerase chain reaction, both IL23R rs10489629 and rs1004819 SNPs were genotyped. The messenger RNA (mRNA) expression levels of IL-23R, IL-23, and IL-17A were determined in peripheral blood mononuclear cells (PBMCs). The serum levels of IL-23 and IL-17A were also determined.
RESULTS RESULTS
The A allele (odds ratio [OR] = 1.52, 95% CI: 1.15-2.01; P = .0030), AA genotype (OR = 2.41, 95% CI: 1.33-4.35; P = .0035), and AG genotype (OR = 2.55, 95% CI: 1.56-4.16, P = .0002) of rs1004819 SNP was significantly associated with increased RA risk. The mRNA expression of IL-17A (fold change = 2.55, P = .00027), IL-23 (fold change = 1.62, P = .0081), and IL-23R (fold change = 1.59, P = .0077) was significantly upregulated in the PBMCs from RA patients compared to that of healthy controls. Serum levels of IL-17A (P = .00019) and IL-23 (P = .00055) was significantly higher in the RA patients compared to the controls. No significant association was detected between patient data and SNPs.
CONCLUSIONS CONCLUSIONS
The IL-23/IL-27 pathway plays a role in RA pathogenesis, but IL23R gene rs1004819 SNP might not be regulating this pathway in RA disease.

Identifiants

pubmed: 36302513
doi: 10.1111/1756-185X.14479
doi:

Substances chimiques

Interleukin-17 0
Receptors, Interleukin 0
Interleukin-23 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

259-266

Subventions

Organisme : Rafsanjan University of Medical Sciences
ID : IR.RUMS.REC.1400.169

Informations de copyright

© 2022 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Références

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
Hojjatipour T, Aslani S, Salimifard S, et al. NK cells-Dr. Jekyll and Mr. Hyde in autoimmune rheumatic diseases. Int Immunopharmacol. 2022;107:108682.
van der Woude D, van der Helm-van AH. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32(2):174-187.
Karami J, Aslani S, Jamshidi A, Garshasbi M, Mahmoudi M. Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review. Gene. 2019;702:8-16.
Padyukov L. Genetics of rheumatoid arthritis. In: Yukinori O, Kazuhiko Y, eds. Seminars in immunopathology. Springer; 2022:1-16.
Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715-725.
McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006;27(1):17-23.
Schinocca C, Rizzo C, Fasano S, et al. Role of the IL-23/IL-17 pathway in rheumatic diseases: an overview. Front Immunol. 2021;12:321.
Kageyama Y, Kobayashi H, Kato N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Modern Rheumatol. 2009;19(6):657-662.
Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168(11):5699-5708.
Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci. 2011;108(23):9560-9565.
Mohammadi FS, Aslani S, Mostafaei S, Jamshidi A, Riahi P, Mahmoudi M. Are genetic variations in IL-21-IL-23R-IL-17A cytokine axis involved in a pathogenic pathway of rheumatoid arthritis? Bayesian hierarchical meta-analysis. J Cell Physiol. 2019;234(10):17159-17171.
Rezaei A, Harsini S, Sadr M, Ziaee V, Rezaei N. Interleukin-23 receptor gene polymorphisms in Iranian patients with juvenile systemic lupus erythematosus. Allergol Immunopathol. 2020;48(1):62-66.
Emami S, Ziaee V, Rezaei A, et al. IL 23R gene polymorphism with juvenile idiopathic arthritis and its association with serum IL-17A. Int J Rheum Dis. 2016;19(11):1189-1196.
Britsemmer K, Ursum J, Gerritsen M, van Tuyl L, van Schaardenburg D. Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria. Ann Rheum Dis. 2011;70(8):1468-1470.
Roe BA, Crabtree JS, Khan AS. DNA isolation and sequencing. John Wiley & Sons; 1996.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101-1108.
Yong Y, Lin H. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97-98.
Zou Q, Zhao Y, Wang Y, Fang Y, Liu Y. Associations between IL-23R gene polymorphisms and the susceptibility of rheumatoid arthritis: a meta-analysis. Artif Cells Nanomed Biotechnol. 2019;47(1):951-956.
Daryabor G, Mahmoudi M, Jamshidi A, et al. Determination of IL-23 receptor gene polymorphism in Iranian patients with ankylosing spondylitis. Eur Cytokine Netw. 2014;25(1):24-29.
Cojocaru-Gofita I, Paulina C, Yeremenko N. The cellular source of IL-17A in the pathogenesis of inflammatory joint diseases. Curr Health Sci J. 2012;38(2):49-53.
Hazlett J, Stamp L, Merriman T, Highton J, Hessian P. IL-23R rs11209026 polymorphism modulates IL-17A expression in patients with rheumatoid arthritis. Genes Immunity. 2012;13(3):282-287.

Auteurs

Mitra Abbasifard (M)

Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Department of Internal Medicine, Ali-Ibn Abi-Talib Hospital, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

Mohammad Reza Mirzaei (MR)

Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Department of Clinical Biochemistry, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

Mahsa Abade (M)

Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

Zahra Bagheri-Hosseinabadi (Z)

Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Department of Clinical Biochemistry, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH